secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bicara Therapeutics Inc. (BCAX)
CIK:        0002023658
Form:       8-K
Filed at:   2026-07-28T12:35:19+00:00
Accession:  0001628280-26-049937
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicara Therapeutics appoints Jeremy Bender and Christy Oliger to board; Kiran Mazumdar-Shaw retires
--------------------------------------------------------------------------------

- Kiran Mazumdar-Shaw resigned from board effective July 28, 2026; no disagreement with company.
- Jeremy Bender (former CEO, Day One Biopharmaceuticals) and Christy Oliger (former SVP, Genentech) appointed to board effective July 28, 2026.
- Board size increased from nine to ten directors; Bender and Oliger each receive initial option award of 38,950 shares.
- New Launch Readiness Committee formed with Kate Haviland as chair, Bender and Oliger as members.
- Appointments support Bicara's transition to commercial-stage focus on ficerafusp alfa.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023658/000162828026049937/0001628280-26-049937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023658/000162828026049937/bcax-20260723.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-049937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer